Citius Pharmaceuticals Files 8-K
Ticker: CTXR · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1506251
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: CTRS
TL;DR
CTRS filed an 8-K, standard reporting, no major news.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on March 18, 2024, to report other events and financial statements. The filing does not contain specific financial figures or details about material events, but it serves as a notification to the SEC.
Why It Matters
This filing indicates that Citius Pharmaceuticals, Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K, indicating standard corporate reporting rather than a significant event or financial disclosure.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- March 18, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- 001-38174 (company_id) — Commission File Number
- 27-3425913 (company_id) — IRS Employer Identification No.
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 18, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 18, 2024.
In which state is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number for Citius Pharmaceuticals, Inc. is 001-38174.
What is the principal executive office address for Citius Pharmaceuticals, Inc.?
The principal executive office address is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-03-18 16:05:22
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0202010-8k_citius.htm (8-K) — 27KB
- ea0202010ex99-1_citius.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-023483.txt ( ) — 221KB
- ctxr-20240318.xsd (EX-101.SCH) — 3KB
- ctxr-20240318_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240318_pre.xml (EX-101.PRE) — 22KB
- ea0202010-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 18, 2024, Citius Pharmaceuticals, Inc. issued a press release to announce that the U.S. Food and Drug Administration has accepted the resubmission of the Company's Biologics License Application for LYMPHIR (denileukin diftitox) for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit is filed herewith: Exhibit No. Description 99.1 Press Release dated March 18, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: March 18, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer